Critical Review in Designing Plant-Based Anticancer Nanoparticles against Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC), accounting for 85% of liver cancer cases, continues to be the third leading cause of cancer-related deaths worldwide. Although various forms of chemotherapy and immunotherapy have been investigated in clinics, patients continue to suffer from high toxicity and undesir...
Saved in:
Main Author: | |
---|---|
Other Authors: | |
Format: | Review |
Published: |
2023
|
Subjects: | |
Online Access: | https://repository.li.mahidol.ac.th/handle/123456789/87933 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Mahidol University |
id |
th-mahidol.87933 |
---|---|
record_format |
dspace |
spelling |
th-mahidol.879332023-07-18T01:03:28Z Critical Review in Designing Plant-Based Anticancer Nanoparticles against Hepatocellular Carcinoma Basu A. Mahidol University Pharmacology, Toxicology and Pharmaceutics Hepatocellular carcinoma (HCC), accounting for 85% of liver cancer cases, continues to be the third leading cause of cancer-related deaths worldwide. Although various forms of chemotherapy and immunotherapy have been investigated in clinics, patients continue to suffer from high toxicity and undesirable side effects. Medicinal plants contain novel critical bioactives that can target multimodal oncogenic pathways; however, their clinical translation is often challenged due to poor aqueous solubility, low cellular uptake, and poor bioavailability. Nanoparticle-based drug delivery presents great opportunities in HCC therapy by increasing selectivity and transferring sufficient doses of bioactives to tumor areas with minimal damage to adjacent healthy cells. In fact, many phytochemicals encapsulated in FDA-approved nanocarriers have demonstrated the ability to modulate the tumor microenvironment. In this review, information about the mechanisms of promising plant bioactives against HCC is discussed and compared. Their benefits and risks as future nanotherapeutics are underscored. Nanocarriers that have been employed to encapsulate both pure bioactives and crude extracts for application in various HCC models are examined and compared. Finally, the current limitations in nanocarrier design, challenges related to the HCC microenvironment, and future opportunities are also discussed for the clinical translation of plant-based nanomedicines from bench to bedside. 2023-07-17T18:03:28Z 2023-07-17T18:03:28Z 2023-06-01 Review Pharmaceutics Vol.15 No.6 (2023) 10.3390/pharmaceutics15061611 19994923 2-s2.0-85163790548 https://repository.li.mahidol.ac.th/handle/123456789/87933 SCOPUS |
institution |
Mahidol University |
building |
Mahidol University Library |
continent |
Asia |
country |
Thailand Thailand |
content_provider |
Mahidol University Library |
collection |
Mahidol University Institutional Repository |
topic |
Pharmacology, Toxicology and Pharmaceutics |
spellingShingle |
Pharmacology, Toxicology and Pharmaceutics Basu A. Critical Review in Designing Plant-Based Anticancer Nanoparticles against Hepatocellular Carcinoma |
description |
Hepatocellular carcinoma (HCC), accounting for 85% of liver cancer cases, continues to be the third leading cause of cancer-related deaths worldwide. Although various forms of chemotherapy and immunotherapy have been investigated in clinics, patients continue to suffer from high toxicity and undesirable side effects. Medicinal plants contain novel critical bioactives that can target multimodal oncogenic pathways; however, their clinical translation is often challenged due to poor aqueous solubility, low cellular uptake, and poor bioavailability. Nanoparticle-based drug delivery presents great opportunities in HCC therapy by increasing selectivity and transferring sufficient doses of bioactives to tumor areas with minimal damage to adjacent healthy cells. In fact, many phytochemicals encapsulated in FDA-approved nanocarriers have demonstrated the ability to modulate the tumor microenvironment. In this review, information about the mechanisms of promising plant bioactives against HCC is discussed and compared. Their benefits and risks as future nanotherapeutics are underscored. Nanocarriers that have been employed to encapsulate both pure bioactives and crude extracts for application in various HCC models are examined and compared. Finally, the current limitations in nanocarrier design, challenges related to the HCC microenvironment, and future opportunities are also discussed for the clinical translation of plant-based nanomedicines from bench to bedside. |
author2 |
Mahidol University |
author_facet |
Mahidol University Basu A. |
format |
Review |
author |
Basu A. |
author_sort |
Basu A. |
title |
Critical Review in Designing Plant-Based Anticancer Nanoparticles against Hepatocellular Carcinoma |
title_short |
Critical Review in Designing Plant-Based Anticancer Nanoparticles against Hepatocellular Carcinoma |
title_full |
Critical Review in Designing Plant-Based Anticancer Nanoparticles against Hepatocellular Carcinoma |
title_fullStr |
Critical Review in Designing Plant-Based Anticancer Nanoparticles against Hepatocellular Carcinoma |
title_full_unstemmed |
Critical Review in Designing Plant-Based Anticancer Nanoparticles against Hepatocellular Carcinoma |
title_sort |
critical review in designing plant-based anticancer nanoparticles against hepatocellular carcinoma |
publishDate |
2023 |
url |
https://repository.li.mahidol.ac.th/handle/123456789/87933 |
_version_ |
1781416150306914304 |